Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor

被引：4
|
作者：
Stocchi, F [1 ]
Vacca, L
Grassini, P
Battaglia, G
Onofrj, M
Valente, M
Ruggieri, S
机构：
[1] IRRCS Neuromed, Pozzilli, IS, Italy
[2] Univ Roma La Sapienza, Dept Neurosci, Rome, Italy
[3] Univ G DAnnunzio, Dept Neurooncol, Chieti, Italy
来源：
NEUROLOGICAL SCIENCES | 2003年 / 24卷 / 03期
关键词：
D O I：
10.1007/s10072-003-0138-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：217 / 218
页数：2
相关论文
共 50 条
  • [11] Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients
    Lamberti, P
    Zoccolella, S
    Iliceto, G
    Armenise, E
    Fraddosio, A
    de Mari, M
    Livrea, P
    [J]. MOVEMENT DISORDERS, 2005, 20 (01) : 69 - 72
  • [12] Role of levodopa in progression of Parkinson's disease
    Roy, S. P.
    Jain, R. S.
    [J]. MOVEMENT DISORDERS, 2013, 28 : S174 - S174
  • [13] Effect of gastrointestinal surgery on the pharmacokinetics of levodopa in Parkinson's disease
    Miyaue, N.
    Nomoto, M.
    Yabe, H.
    Yamanishi, Y.
    Tada, S.
    Ando, R.
    Kubo, M.
    Nagai, M.
    [J]. MOVEMENT DISORDERS, 2019, 34 : S142 - S142
  • [14] Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
    G. Arabia
    M. Zappia
    D. Bosco
    L. Crescibene
    A. Bagalà
    L. Bastone
    M. Caracciolo
    M. Scornaienghi
    A. Quattrone
    [J]. Neurological Sciences, 2002, 23 : s53 - s54
  • [15] Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease
    Mueller, Thomas
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (05) : 403 - 414
  • [16] Body weight influences pharmacokinetics of levodopa in Parkinson's disease
    Zappia, M
    Crescibene, L
    Arabia, G
    Nicoletti, G
    Bagalà, A
    Bastone, L
    Caracciolo, M
    Bonavita, S
    Di Costanzo, A
    Scornaienchi, M
    Gambardella, A
    Quattrone, A
    [J]. CLINICAL NEUROPHARMACOLOGY, 2002, 25 (02) : 79 - 82
  • [17] Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease
    Arabia, G
    Zappia, M
    Bosco, D
    Crescibene, L
    Bagalà, A
    Bastone, L
    Caracciolo, M
    Scornaienghi, M
    Quattrone, A
    [J]. NEUROLOGICAL SCIENCES, 2002, 23 (Suppl 2) : S53 - S54
  • [18] The influence of levodopa and the COMT inhibitor on serum vitamin B12 and folate levels in Parkinson's disease patients
    Triantafyllou, N. I.
    Kararizou, E.
    Angelopoulos, E.
    Tsounis, S.
    Boufidou, F.
    Evangelopoulos, M. E.
    Nikolaou, C.
    Vassilopoulos, D.
    [J]. EUROPEAN NEUROLOGY, 2007, 58 (02) : 96 - 99
  • [19] The role of COMT inhibition in the treatment of Parkinson's disease
    Poewe, W
    [J]. NEUROLOGY, 2004, 62 (01) : S31 - S38
  • [20] Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson's Disease
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Stocchi, F.
    Antonini, A.
    Moreira, J.
    Rocha, J.
    Soares-da-Silva, P.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 440 - 441
12345